Johnson & Johnson (NYSE:JNJ) Updates FY 2026 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 11.430-11.630 for the period, compared to the consensus estimate of 11.480. The company issued revenue guidance of $99.5 billion-$100.5 billion, compared to the consensus revenue estimate of $98.7 billion.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Citigroup lifted their price target on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Bank of America upped their target price on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Royal Bank Of Canada set a $240.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, December 17th. Finally, Argus set a $210.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $213.33.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $218.09 on Wednesday. The business’s 50-day simple moving average is $206.92 and its 200-day simple moving average is $188.05. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $220.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market cap of $525.43 billion, a price-to-earnings ratio of 21.05, a P/E/G ratio of 2.25 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, missing analysts’ consensus estimates of $2.53 by ($0.07). The firm had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J forecast 2026 sales and profit above Wall Street estimates, and said its outlook already factors in a “hundreds of millions” hit from a recent drug-pricing deal — signaling durable underlying growth despite a pricing headwind. Johnson & Johnson forecasts 2026 profit above Wall Street estimates
• Positive Sentiment: J&J reported strong Q4 and full?year 2025 results, driven by oncology and autoimmune drug sales, and management described 2025 as a “catapult year” for the portfolio and pipeline — an operational beat that supports the premium valuation. Johnson & Johnson reports Q4 and Full-Year 2025 results
• Positive Sentiment: Late-stage clinical momentum: J&J said CAPLYTA showed stronger remission results in Phase 3 MDD data, which can lift sentiment around future revenue streams if regulatory paths remain clear. CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says
• Neutral Sentiment: Analysts have updated models ahead of and after the print — some raising targets on stronger pharma/MedTech momentum, others flagging biosimilar pressure and China headwinds; net impact to estimates is mixed. Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
• Negative Sentiment: Market reaction: shares dropped in premarket trade despite results — likely profit?taking after a strong run and investors re?weighting around forward risks. JNJ Earnings: Johnson & Johnson Stock Falls despite Strong Q4 Results
• Negative Sentiment: Legal risk remains: talc-related litigation is moving toward trial, keeping an overhang on valuation despite operational strength. Johnson & Johnson (JNJ) Earnings Arrive as Talc Lawsuits Move Toward Trial
• Negative Sentiment: Broader market sentiment turned risk?off ahead of political events, which pressured cyclical and large-cap healthcare stocks and likely contributed to the stock’s near-term pullback. Markets Switch to “Risk-Off” Ahead of Trump at Davos

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Abel Hall LLC acquired a new stake in Johnson & Johnson during the third quarter worth $419,000. Harvest Investment Services LLC raised its position in Johnson & Johnson by 21.4% in the third quarter. Harvest Investment Services LLC now owns 2,826 shares of the company’s stock worth $524,000 after purchasing an additional 499 shares in the last quarter. Keystone Financial Group lifted its stake in Johnson & Johnson by 10.1% during the third quarter. Keystone Financial Group now owns 51,405 shares of the company’s stock worth $9,774,000 after purchasing an additional 4,733 shares during the period. Conservest Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $211,000. Finally, Morningstar Investment Management LLC raised its holdings in shares of Johnson & Johnson by 1,999.4% in the 3rd quarter. Morningstar Investment Management LLC now owns 98,377 shares of the company’s stock worth $18,241,000 after buying an additional 93,691 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.